Novo Nordisk

Novo Nordisk A/S (NYSE: NVO), headquartered in Bagsværd, Denmark, is a premier global healthcare company with a century-long legacy of driving change to defeat serious chronic diseases. Founded in 1923, the company built an unrivaled foundation in diabetes care, which has since expanded into pioneering treatments for obesity, cardiovascular disease, MASH, and rare blood and endocrine disorders such as haemophilia and sickle cell disease. Operating on a massive global scale, Novo Nordisk is dedicated to discovering, developing, and manufacturing innovative biological medicines and making them accessible to patients worldwide.

The company is globally recognized for its revolutionary advancements in GLP-1 (glucagon-like peptide-1) therapies, which have fundamentally transformed the treatment landscapes for type 2 diabetes and chronic weight management. Moving through 2026, Novo Nordisk continues to push the boundaries of medical science with major clinical breakthroughs, including demonstrating the potential for oral semaglutide as a primary therapy for children and adolescents with type 2 diabetes, and advancing novel drug classes like Etavopivat for sickle cell disease. Furthermore, the company is aggressively integrating next-generation technologies into its operations, highlighted by its recent 2026 strategic partnership with OpenAI to transform how life-saving medicines are discovered and delivered.

Beyond its pharmaceutical innovations, Novo Nordisk is deeply guided by its "Circular for Zero" environmental strategy, which targets zero environmental impact across its entire global value chain. The company actively combats the spread of falsified medicines while focusing heavily on expanding global affordability and access to its treatments. Navigating an era of unprecedented demand for its metabolic portfolios, Novo Nordisk remains a dominant, highly influential force in the global pharmaceutical industry, successfully balancing exceptional financial growth with its enduring mission to eradicate chronic disease and improve the lives of millions.